Onconova Therapeutics Inc. Warrants
ONTXW
NASDAQ Capital Market0.07
USD
-0.02
- -
Return %
Stock
S&P500
1Y
- -
19.01
3Y
- -
65.48
5Y
- -
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- United States of America
- IPO Date
- Jan 31, 2022
- Similar Companies
- Business
- Onconova Therapeutics Inc., now operating under Traws Pharma, Inc. following a May 2024 business combination with Trawsfynydd Therapeutics, is a clinical-stage biopharmaceutical entity engaged in the discovery and development of novel treatments for both cancer and respiratory viral diseases. The company's oncology pipeline features narazaciclib (ON 123300), a multi-targeted kinase inhibitor currently in Phase I studies for solid tumors and hematological malignancies, and rigosertib, an oral agent being evaluated in investigator-initiated studies for conditions like K-Ras mutated non-small cell lung cancer, myelodysplastic syndromes, and acute myeloid leukemia. Their expanded focus now includes antiviral candidates such as Viroksavir for influenza and Travaltrelvir for COVID-19, which are slated for Phase 2 clinical trials. The ONTXW ticker represents warrants issued by Onconova Therapeutics, Inc., granting holders the right, but not the obligation, to acquire a specified number of the company's common shares at a predetermined exercise price within a particular timeframe. These warrants enable investors to potentially participate in the future upside of the company's stock.